Friday, March 4th 2016
| 09:00 | 10:00 |
Mechanisms of inhibitor development Chair: Sebastien Lacroix Desmazes (France) |
|
Allo and autoantibodies Sebastien Lacroix Desmazes (France) |
||
|
The role of B and T cells and novel therapeutical approach David W Scott (USA) |
||
| Discussion | ||
| 10:00 | 11:00 |
Inhibitor data collection systems Chair: Mike Makris (UK) |
|
National registries: UK, French, Canadian Jenny Goudemand (France) |
||
|
European data collections on previosuly untreated patients (PUPs) Marijke van den Berg (the Netherlands) |
||
|
Inhibitors in previously treated patients (PTP) Mike Makris (UK) |
||
| Discussion | ||
| 11:30 | 12:30 | Chair: Marijke van den Berg (the Netherlands) |
|
Inhibitors in mild hemophilia. INSIGHT study Alice S. van Velzen (the Netherlands) |
||
| Discussion | ||
|
Clinical significance of low and high titer inhibitors Elena Santagostino (Italy) |
||
| Discussion | ||
| 14:00 | 15:30 |
Inhibitor development in previoiusly untreated patients (PUPs) Chair: Keith W. Hoots (USA) |
|
Role of von Willebrand factor for concentrate immunogenicity David Lillicrap (Canada) |
||
|
Results of SIPPET study Frits R. Rosendaal (the Netherlands) |
||
|
How EMA and FDA are tackling the problem of inhibitor development Anneliese Hilger (EMA) and Jay Epstein, Zuben E. Sauna (FDA) |
||
| Discussion | ||
| 15:30 | 16:00 |
Genetics of inhibitors. How next generation sequencing can help to better understand the inhibitor risk Chair: Elena Santagostino (Italy) |
| 16:20 | 16:40 |
Cost of inhibitor treatment. A pharmacoeconomical perspective Chair: Frits R. Rosendaal (the Netherlands) |
| 16:40 | 17:20 |
Treatment of inhibitors Chair: Flora Peyvandi (Italy) and David Lillicrap (Canada) |
|
Our experience on bypassing therapy in patients with inhibitors. Success and failures: what else is necessary? Maria Elisa Mancuso (Italy) |
||
|
The role of non replacement products (antithrombin, anti TFPI, bi-specific antibody) David Lillicrap (Canada) |
||
| 17:20 | 18:00 |
Optimal diagnosis and treatment of patients with acquired hemophilia Chair: Pier Mannuccio Mannucci (Italy) |
